HBOC-201: Clinical Trials

5 trials of HBOC-201, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 no longer available, 1 enrolling by invitation, 1 terminated. 1 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable1Enrolling by invitation 1
Phase 21Terminated 1

Follow HBOC-201: new trials by email Literature Review of HBOC-201 trials Research Report on HBOC-201

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia
HBOC-201 - Anemia
Not applicableEnrolling by invitationEnglewood Hospital and Medical Center502013-10-012025-04-13
Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia
Hemoglobin glutamer 250 - bovine, 6% Hydroxyethylstarch - Peripheral Vascular Disease
Phase 2TerminatedBiopure Corporation162006-05-012008-05-16
Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia
HBOC-201 - Anemia Severe
No longer availableMichael Boisen2026-07-20
Expanded Access Protocol Using HBOC-201
HBOC-201 - Anemia
No longer availableJohns Hopkins University2025-10-23
HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option
HBOC-201 - Anemia
No longer availableMauricio Lynn2024-12-20

Conditions studied

Anemia (3)  ·  Chronic Limb-Threatening Ischemia (1)  ·  Hematologic Diseases (1)  ·  Peripheral Vascular Diseases (1)

Sponsors

Biopure Corporation (1)  ·  Englewood Hospital and Medical Center (1)  ·  Johns Hopkins University (1)  ·  Mauricio Lynn (1)  ·  Michael Boisen (1)

Countries

United States (4)  ·  South Africa (1)  ·  United Kingdom (1)

Top investigators

A. Gerson Greenburg, MD, Ph.D. (1)  ·  Carmine Gianatiempo, MD (1)  ·  Mauricio Lynn (1)  ·  Steven M Frank, MD (1)